1999
DOI: 10.1006/cimm.1999.1569
|View full text |Cite
|
Sign up to set email alerts
|

Correolide and Derivatives Are Novel Immunosuppressants Blocking the Lymphocyte Kv1.3 Potassium Channels

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

3
106
1

Year Published

2001
2001
2013
2013

Publication Types

Select...
5
2
1

Relationship

0
8

Authors

Journals

citations
Cited by 83 publications
(110 citation statements)
references
References 20 publications
3
106
1
Order By: Relevance
“…These data illustrate that Kv1.3 up-regulation during G 1 is a prerequisite for G 1 ͞S transition. In fact, Kv1.3 has been implicated in the proliferation of other cell types (24,31,32).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…These data illustrate that Kv1.3 up-regulation during G 1 is a prerequisite for G 1 ͞S transition. In fact, Kv1.3 has been implicated in the proliferation of other cell types (24,31,32).…”
Section: Discussionmentioning
confidence: 99%
“…To examine whether I K expressed by NG2 ϩ OPs in the SVZ͞developing white matter contain or comprise Kv1.3 subunits, we studied the effects of the Kv1.3 channel blockers, r-agitoxin (AgTx) and r-margatoxin (MgTx), at concentrations shown to be selective for Kv1.3-containing channels (21)(22)(23)(24). Both of these toxins only partially inhibited I K in these cells (Fig.…”
Section: Ops In Acutely Isolated Slices Display Ik That Are Partiallymentioning
confidence: 99%
“…Earlier studies showed that the Kv1.3 blockers margatoxin, correolide, and kaliotoxin suppressed delayed-type hypersensitivity (DTH) in miniswine and rats (5,69,70). Based on these results, investigators in the field (5, 71) concluded that Kv1.3 blockers inhibited the primary immune response and caused generalized immunosuppression.…”
Section: Cd27mentioning
confidence: 99%
“…In proof-of-concept studies in rats, Kv1.3 blockers have been shown to ameliorate adoptive experimental autoimmune encephalomyelitis induced by myelin-specific memory T cells (16,70), a model for MS, and to prevent inflammatory bone resorption in experimental periodontal disease caused mainly by memory cells (81). Several small-molecule Kv1.3 inhibitors with nanomolar potency have been developed over the last decade (WIN-17317, CP-339818, U.K.-78,282, correolide, trans-N-propylcarbamoyloxy-PAC, sulfamidebenzamidoindanes, tetraphenylporphyrins, dichlorophenylpyrazolopyrimidines, chalcones, and Psora-4 (6,7,31,69,82,83)), and the continuing development of more selective and potent Kv1.3 blockers may make Kv1.3-based immunomodulation for autoimmune disorders a reality.…”
Section: Cd27mentioning
confidence: 99%
“…Kv1.3 is the primary regulator of Ca 2ϩ signaling in human quiescent T cells. Selective blockade of Kv1.3, but not IKCa1, suppresses mitogenstimulated cytokine production and proliferation of these cells in vitro (14)(15)(16)(17) and the delayed type hypersensitivity response in vivo (6,18,19). Transcriptional up-regulation during mitogenesis results in IKCa1 becoming the main regulator of Ca 2ϩ signaling in human activated lymphocytes, and selective IKCa1 blockade suppresses cytokine production and mitogenesis of preactivated cells (17,20,21).…”
mentioning
confidence: 99%